Presented at ESMO Virtual Congress 2020, a recent study compared results on apalutamide administered in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) between real-world data from an international named patient program (NPP) and the phase 3 SPARTAN clinical trial and found that the results were similar. In an interview with i3 Health, lead study author Professor Heather Payne, MBBS, FRCP, FRCR of the University College Hospital, discusses the significance of these res...
Olaparib prolongs overall survival compared with enzalutamide or abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) and gene alterations in BRCA1, BRCA2, or ATM, according to the final survival analysis of the phase 3 PROfound trial. These results were presented yesterday at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 and simultaneously published in the New England Journal of Medicine. "Metastatic castration-resistant prostate cancer r...
In a recent study presented at ESMO Virtual Congress 2020, data reported on apalutamide (APA) administered in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) is comparable between real-world data from an international named patient program (NPP) and phase 3 SPARTAN clinical trial results. For the NPP, a total of 556 patients with nmCRPC received APA pre-approval administration. After a follow-up of 10 months for both cohorts, APA treatment continuation was evaluated an...
In this interview, Nicholas Vogelzang, MD, speaks with i3 Health about the recent FDA approval of rucaparib (Rubraca®, Clovis Oncology, Inc.) for the treatment of patients with metastatic BRCA-mutated castration-resistant prostate cancer (CRPC) who previously received one line of taxane-based chemotherapy and at least one line of androgen receptor-directed therapy. Dr. Vogelzang, Clinical Professor of Medicine at the University of Nevada School of Medicine and one of the investigators of the TRI...
The FDA has approved olaparib (LynparzaTM, AstraZeneca Pharmaceuticals LP) for adult patients with homologous recombination repair (HRR)–mutated metastatic castration-resistant prostate cancer (CRPC) who experience disease progression after treatment with enzalutamide or abiraterone acetate. In addition, the FDA approved two companion diagnostic devices: FoundationOne® CDx (Foundation Medicine, Inc.), for the identification of HRR gene alterations, and BRACAnalysis CDx®(Myriad Genetics, Inc...